Information Provided By: 
Fly News Breaks for February 22, 2017
EXAS
Feb 22, 2017 | 08:31 EDT
As previously reported, Roth Capital analyst Chris Lewis upgraded Exact Sciences to Buy from Neutral after the company announced Q4 revenues in-line with its pre-announcement beat driven by strong volumes and higher ASPs, and unveiled 2017 guidance above expectations. The analyst believes Exact Sciences is well-positioned to sustain its notable commercial launch trajectory over the coming years. Lewis also raised his price target on the shares to $26 from $15.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
